<p>Electromed, Inc.（纽约证券交易所代码：ELMD - 免费报告）- B. Riley 的研究分析师在 11 月 13 日星期四发布的报告中上调了 Electromed 2026 年第二季度每股收益（EPS）预期。B. Riley 分析师 A. Schock 现在预计该公司本季度每股收益为 0.28 美元，高于之前预测的 0.25 美元。B. Riley 还发布了 Electromed 2026 年第三季度每股收益 0.26 美元、2026 财年每股收益 1.09 美元、2027 年第一季度每股收益 0.31 美元、2027 年第二季度每股收益 0.34 美元、2027 年第三季度每股收益 0.32 美元、2027 年第四季度每股收益 0.38 美元以及 2027 财年每股收益 1.36 美元的预期。</p>
<p>其他研究分析师也发布了关于该股票的研究报告。Lake Street Capital 在 8 月 27 日星期三的研究报告中开始覆盖 Electromed 的股票。他们给予该公司的 “买入” 评级，并设定了 36.00 美元的目标价。Roth Capital 在星期四的研究报告中重申了 “买入” 评级，并将 Electromed 的目标价上调至 36.00 美元（之前为 35.00 美元）。Loop Capital 在 8 月 27 日星期三的研究报告中设定了 Electromed 的目标价为 36.00 美元。最后，Zacks Research 在 10 月 27 日星期一的研究报告中将 Electromed 的评级从 “强力买入” 下调至 “持有”。一位分析师给予该股票 “强力买入” 评级，两位给予 “买入” 评级，一位给予 “持有” 评级。根据 MarketBeat 的数据，Electromed 的平均评级为 “买入”，平均目标价为 36.50 美元。</p>
<p><strong>获取我们最新的 ELMD 股票分析</strong></p>
<h2>Electromed 股价下跌 5.0%</h2>
<p>在星期五的午盘交易中，ELMD 股价下跌 1.31 美元，报 25.04 美元。该股票交易量为 7,093 股，而其平均交易量为 77,355 股。该公司的 50 日移动平均线为 24.60 美元，200 日移动平均线为 21.98 美元。Electromed 的 1 年最低价为 17.73 美元，1 年最高价为 35.56 美元。该公司的市值为 2.0974 亿美元，市盈率为 33.39，贝塔值为 0.40。</p>
<h2>对 Electromed 的对冲基金看法</h2>
<p>几家对冲基金最近增加或减少了对该股票的持仓。Dimensional Fund Advisors LP 在第三季度将其在 Electromed 的持股增加了 0.4%。Dimensional Fund Advisors LP 现在拥有 190,103 股该公司的股票，价值 4,667,000 美元，此前在上个季度购买了 696 股。American Century Companies Inc.在第二季度将其在 Electromed 的持股增加了 3.1%。American Century Companies Inc.现在拥有 32,031 股该公司的股票，价值 704,000 美元，此前在上个季度购买了 969 股。Spire Wealth Management 在第二季度将其在 Electromed 的持股增加了 22.7%。Spire Wealth Management 现在拥有 5,405 股该公司的股票，价值 119,000 美元，此前在上个季度购买了 1,000 股。Raymond James Financial Inc.在第二季度将其在 Electromed 的持股增加了 1.8%。Raymond James Financial Inc.现在拥有 58,331 股该公司的股票，价值 1,283,000 美元，此前在上个季度购买了 1,053 股。最后，新泽西州警察和消防员退休系统在第二季度购买了 Electromed 的新股份，价值 32,000 美元。目前，40.82% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Electromed 的内部买卖情况</h2>
<p>在相关消息中，董事 Andrew Summers 在 9 月 11 日星期四出售了 3,153 股该公司的股票。该股票以平均价格 24.42 美元出售，总交易额为 76,996.26 美元。该交易已在与证券交易委员会的法律文件中披露，可以通过此链接访问。公司内部人士持有该公司股票的 10.50%。</p>
<h2>Electromed 公司简介</h2>
<p>（获取免费报告）</p>
<p>Electromed, Inc.开发、制造、营销和销售气道清理治疗及相关产品，应用高频胸壁振荡（HFCWO）治疗，服务于美国及国际各年龄段的患者。该公司为肺功能受损的患者提供 SmartVest 气道清理系统，包括支气管扩张症和囊性纤维化患者，以及神经肌肉疾病患者，如脑瘫和肌萎缩侧索硬化症；SmartVest SQL 系统；SmartVest Clearway 系统，包括一个充气治疗服、一个可编程气脉冲发生器和一个专利单管道，将气脉冲从发生器输送到服装，以在胸壁上产生振荡压力；以及 SmartVest Connect，一种无线技术，允许医生与患者之间的数据连接，以跟踪治疗效果并协作治疗决策。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Electromed</li>
<li>支撑和阻力的基础知识</li>
<li>CRWD 股票在财报前达到关键拐点</li>
<li>什么是分红挑战者？</li>
<li>Rigetti 的第三季度失利揭示量子资金和时机压力</li>
<li>三只 2021 年前景良好的金融科技股票</li>
<li>Monolithic Power 在 2025 年大幅上涨——是时候买入还是持有？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMTUQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMTUQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Electromed 吗？</h2>
<p>在你考虑 Electromed 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Electromed 并不在名单上。</p>
<p>虽然 Electromed 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ELMD

<p>B. Riley 将 Electromed 2026 年第二季度每股收益预期从 0.25 美元上调至 0.28 美元，显示出乐观的前景。分析师给予 Electromed "买入" 评级，平均目标价为 36.50 美元。尽管预测积极，Electromed 的股票仍下跌 5%，报 25.04 美元。对冲基金和内部人士正在积极交易该股票，机构投资者持有 40.82% 的股份</p>

<p>Electromed, Inc. (NYSE:ELMD - Free Report) - Research analysts at B. Riley lifted their Q2 2026 earnings per share (EPS) estimates for Electromed in a report issued on Thursday, November 13th. B. Riley analyst A. Schock now anticipates that the company will post earnings per share of $0.28 for the quarter, up from their previous forecast of $0.25. B. Riley also issued estimates for Electromed's Q3 2026 earnings at $0.26 EPS, FY2026 earnings at $1.09 EPS, Q1 2027 earnings at $0.31 EPS, Q2 2027 earnings at $0.34 EPS, Q3 2027 earnings at $0.32 EPS, Q4 2027 earnings at $0.38 EPS and FY2027 earnings at $1.36 EPS.</p>
<div class="lb-trans"><p>Electromed, Inc.（纽约证券交易所代码：ELMD - 免费报告）- B. Riley 的研究分析师在 11 月 13 日星期四发布的报告中上调了 Electromed 2026 年第二季度每股收益（EPS）预期。B. Riley 分析师 A. Schock 现在预计该公司本季度每股收益为 0.28 美元，高于之前预测的 0.25 美元。B. Riley 还发布了 Electromed 2026 年第三季度每股收益 0.26 美元、2026 财年每股收益 1.09 美元、2027 年第一季度每股收益 0.31 美元、2027 年第二季度每股收益 0.34 美元、2027 年第三季度每股收益 0.32 美元、2027 年第四季度每股收益 0.38 美元以及 2027 财年每股收益 1.36 美元的预期。</p>
</div><p>Other research analysts have also issued research reports about the stock. Lake Street Capital initiated coverage on shares of Electromed in a research note on Wednesday, August 27th. They issued a &#34;buy&#34; rating and a $36.00 price objective for the company. Roth Capital reissued a &#34;buy&#34; rating and issued a $36.00 price target (up previously from $35.00) on shares of Electromed in a research report on Thursday. Loop Capital set a $36.00 price target on shares of Electromed in a research note on Wednesday, August 27th. Finally, Zacks Research lowered Electromed from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, Electromed has an average rating of &#34;Buy&#34; and an average price target of $36.50.</p>
<div class="lb-trans"><p>其他研究分析师也发布了关于该股票的研究报告。Lake Street Capital 在 8 月 27 日星期三的研究报告中开始覆盖 Electromed 的股票。他们给予该公司的 “买入” 评级，并设定了 36.00 美元的目标价。Roth Capital 在星期四的研究报告中重申了 “买入” 评级，并将 Electromed 的目标价上调至 36.00 美元（之前为 35.00 美元）。Loop Capital 在 8 月 27 日星期三的研究报告中设定了 Electromed 的目标价为 36.00 美元。最后，Zacks Research 在 10 月 27 日星期一的研究报告中将 Electromed 的评级从 “强力买入” 下调至 “持有”。一位分析师给予该股票 “强力买入” 评级，两位给予 “买入” 评级，一位给予 “持有” 评级。根据 MarketBeat 的数据，Electromed 的平均评级为 “买入”，平均目标价为 36.50 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on ELMD</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 ELMD 股票分析</strong></p>
</div><h2>Electromed Trading Down 5.0%</h2>
<div class="lb-trans"><h2>Electromed 股价下跌 5.0%</h2>
</div><p>ELMD traded down $1.31 during mid-day trading on Friday, hitting $25.04. 7,093 shares of the stock were exchanged, compared to its average volume of 77,355. The firm's fifty day moving average is $24.60 and its two-hundred day moving average is $21.98. Electromed has a 1-year low of $17.73 and a 1-year high of $35.56. The company has a market cap of $209.74 million, a PE ratio of 33.39 and a beta of 0.40.</p>
<div class="lb-trans"><p>在星期五的午盘交易中，ELMD 股价下跌 1.31 美元，报 25.04 美元。该股票交易量为 7,093 股，而其平均交易量为 77,355 股。该公司的 50 日移动平均线为 24.60 美元，200 日移动平均线为 21.98 美元。Electromed 的 1 年最低价为 17.73 美元，1 年最高价为 35.56 美元。该公司的市值为 2.0974 亿美元，市盈率为 33.39，贝塔值为 0.40。</p>
</div><h2>Hedge Funds Weigh In On Electromed</h2>
<div class="lb-trans"><h2>对 Electromed 的对冲基金看法</h2>
</div><p>Several hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its holdings in Electromed by 0.4% during the third quarter. Dimensional Fund Advisors LP now owns 190,103 shares of the company's stock worth $4,667,000 after purchasing an additional 696 shares in the last quarter. American Century Companies Inc. boosted its holdings in shares of Electromed by 3.1% in the 2nd quarter. American Century Companies Inc. now owns 32,031 shares of the company's stock valued at $704,000 after buying an additional 969 shares in the last quarter. Spire Wealth Management grew its position in shares of Electromed by 22.7% in the 2nd quarter. Spire Wealth Management now owns 5,405 shares of the company's stock valued at $119,000 after buying an additional 1,000 shares during the last quarter. Raymond James Financial Inc. raised its stake in Electromed by 1.8% during the 2nd quarter. Raymond James Financial Inc. now owns 58,331 shares of the company's stock worth $1,283,000 after acquiring an additional 1,053 shares in the last quarter. Finally, Police &amp; Firemen s Retirement System of New Jersey purchased a new stake in Electromed in the second quarter valued at $32,000. 40.82% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近增加或减少了对该股票的持仓。Dimensional Fund Advisors LP 在第三季度将其在 Electromed 的持股增加了 0.4%。Dimensional Fund Advisors LP 现在拥有 190,103 股该公司的股票，价值 4,667,000 美元，此前在上个季度购买了 696 股。American Century Companies Inc.在第二季度将其在 Electromed 的持股增加了 3.1%。American Century Companies Inc.现在拥有 32,031 股该公司的股票，价值 704,000 美元，此前在上个季度购买了 969 股。Spire Wealth Management 在第二季度将其在 Electromed 的持股增加了 22.7%。Spire Wealth Management 现在拥有 5,405 股该公司的股票，价值 119,000 美元，此前在上个季度购买了 1,000 股。Raymond James Financial Inc.在第二季度将其在 Electromed 的持股增加了 1.8%。Raymond James Financial Inc.现在拥有 58,331 股该公司的股票，价值 1,283,000 美元，此前在上个季度购买了 1,053 股。最后，新泽西州警察和消防员退休系统在第二季度购买了 Electromed 的新股份，价值 32,000 美元。目前，40.82% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Insider Buying and Selling at Electromed</h2>
<div class="lb-trans"><h2>Electromed 的内部买卖情况</h2>
</div><p>In related news, Director Andrew Summers sold 3,153 shares of the business's stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $24.42, for a total transaction of $76,996.26. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.50% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 Andrew Summers 在 9 月 11 日星期四出售了 3,153 股该公司的股票。该股票以平均价格 24.42 美元出售，总交易额为 76,996.26 美元。该交易已在与证券交易委员会的法律文件中披露，可以通过此链接访问。公司内部人士持有该公司股票的 10.50%。</p>
</div><h2>Electromed Company Profile</h2>
<div class="lb-trans"><h2>Electromed 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.</p>
<div class="lb-trans"><p>Electromed, Inc.开发、制造、营销和销售气道清理治疗及相关产品，应用高频胸壁振荡（HFCWO）治疗，服务于美国及国际各年龄段的患者。该公司为肺功能受损的患者提供 SmartVest 气道清理系统，包括支气管扩张症和囊性纤维化患者，以及神经肌肉疾病患者，如脑瘫和肌萎缩侧索硬化症；SmartVest SQL 系统；SmartVest Clearway 系统，包括一个充气治疗服、一个可编程气脉冲发生器和一个专利单管道，将气脉冲从发生器输送到服装，以在胸壁上产生振荡压力；以及 SmartVest Connect，一种无线技术，允许医生与患者之间的数据连接，以跟踪治疗效果并协作治疗决策。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Electromed</li>
<li>The Basics of Support and Resistance</li>
<li>CRWD Stock Hits Key Inflection Point Ahead of Earnings</li>
<li>What Are Dividend Challengers?</li>
<li>Rigetti’s Q3 Miss Reveals Quantum Funding and Timing Pressures</li>
<li>3 Fintech Stocks With Good 2021 Prospects</li>
<li>Monolithic Power Surges in 2025—Time to Buy or Hold?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Electromed</li>
<li>支撑和阻力的基础知识</li>
<li>CRWD 股票在财报前达到关键拐点</li>
<li>什么是分红挑战者？</li>
<li>Rigetti 的第三季度失利揭示量子资金和时机压力</li>
<li>三只 2021 年前景良好的金融科技股票</li>
<li>Monolithic Power 在 2025 年大幅上涨——是时候买入还是持有？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMTUQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=ELMD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Electromed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Electromed 吗？</h2>
</div><p>Before you consider Electromed, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Electromed 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Electromed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Electromed 并不在名单上。</p>
</div><p>While Electromed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Electromed 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

B. Riley 对 Electromed 第二季度的收益预期持乐观态度